Can serum interleukin-2 receptor alpha predict lymph node metastasis in early gastric cancer? by Baik, Yong-Hae et al.
ORIGINAL ARTICLE
Copyright © 2012, the Korean Surgical Society
J Korean Surg Soc 2012;82:143-148
http://dx.doi.org/10.4174/jkss.2012.82.3.143 JKSS
Journal of the Korean Surgical Society
 pISSN 2233-7903ㆍeISSN 2093-0488
Received April 27, 2011, Revised September 21, 2011, Accepted October 31, 2011
Correspondence to: Sung Kim
Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, 
Korea
Tel: ＋82-2-3410-0294, Fax: ＋82-2-3410-0926, E-mail: sungkimm@smc.samsung.co.kr
cc  Journal of the Korean Surgical Society is an Open Access Journal. All articles are distributed under the terms of the Creative Commons 
Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, 
distribution, and reproduction in any medium, provided the original work is properly cited.
Can serum interleukin-2 receptor alpha predict lymph 
node metastasis in early gastric cancer?
Yong-Hae Baik, Ji Yeong An
1, Jae-Hyung Noh
2, Tae-Sung Sohn
2, Sung Kim
2
Department of Surgery, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Goyang, 
1Department of 
Surgery, Severance Hospital, Yonsei University College of Medicine, 
2Department of Surgery, Samsung Medical Center, 
Sungkyunkwan University School of Medicine, Seoul, Korea
Purpose: Although local resection like endoscopic mucosal resection for early gastric cancer is accepted as a treatment op-
tion, one of the most important drawbacks of such an approach is the inability to predictlymph node metastasis. The aim of 
this study was to evaluate the serum soluble receptor alpha for interleukin-2 (IL-2Rα) level as a predictor of lymph node 
metastasis in the patients with early gastric cancer. Methods: Assessment of pre-operative serum IL-2Rα levels was per-
formed on 86 patients with early gastric cancer treated by gastrectomies combined with D2 lymph node resections and 20 
healthy controls at Samsung Medical Center. Data on patient age and gender, tumor size, depth of invasion, histologic differ-
entiation, and endoscopic findings were reviewed post-operatively. The submucosal lesions were divided into three layers 
(sm1, sm2, and sm3) in accordance with the depth of invasion. Results: Lymph node metastasis was observed in 16 patients 
(18.6%). Statistically, the serum IL-2Rα level was an important predictive factor of lymph node metastasis in undifferentiated 
gastric cancer, and the cut-off point for the predictive value of serum IL-2Rα level was 200 U/mL. Conclusion: The serum 
IL-2Rα level might be a good predictor of lymph node metastasis in undifferentiated early gastric cancer.
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INTRODUCTION
The gastric cancer mortality rate has been decreasing 
worldwide, but remains the second leading cause of can-
cer-related deaths. In an attempt to improve the quality of 
life in patients undergoing early gastric cancer treatment, 
endoscopic mucosal resection (EMR), laparoscopic-assi-
sted gastrectomy, and robotic surgery have been in-
troduced [1-3]. According to the pretreatment cancer 
stage, we can be choosing optimal treatment modality. 
When Following EMR, the permanent pathologic report 
indicates the tumor has invaded the submucosal layer, or 
tumor differentiation was confirmed to be an undif-
ferentiated type, there is a high risk of lymph node meta-
stasis and further treatment may be necessary, including 
lymph node dissection [4]. Indeed, lymph node metastasis 
is the most significant risk factor for recurrence and sur-
vival [5]. If we had known the lymph node metastasis be-Yong-Hae Baik, et al.
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fore EMR, we must choose other treatment modality 
which related radical surgery with lymph node dissection 
(even D2 is possible) such as laparoscopic-assisted gas-
trectomy, or robotic surgery. 
There are many diagnostic tools for lymph node meta-
stasis in gastric cancer, endoscopic ultrasonography and 
c o m p u t e d  t o m o g r a p h y  ( C T )  i s  used for prediction of 
lymph node metastasis, but the specificity of any pre-oper-
ative diagnostic tool is limited [6]. Thus, additional meth-
ods to predict lymph node metastasis would be useful in 
determining what types of treatment methods to be 
applied. Specifically, an easily measureable serum cyto-
kine which predicted lymph node metastasis in early gas-
tric cancer patients would be an important diagnostic tool.
Smith [7] reported that interleukin (IL)-2 stimulates 
macrophages in a similar manner to helper T-cells, cyto-
toxic T-cells, B-cells, and natural killer cells. 
When IL-2 receptor alpha (IL-2Rα) is activated, the solu-
ble form is released into the serum, thus we can assess the 
level of IL-2Rα in the serum. In colorectal and breast can-
cer patients, an elevation in the serum IL-2Rα level in-
dicates disease progression to stage IV or liver metastasis 
with colorectal cancer, and distant metastasis in breast 
cancer [8]. How ev er , in gastric cancer patients, an ele-
vation of serum IL-2Rα level is associated with stage pro-
gression, but in case of lymph node metastasis such associ-
ation was not well established.
Thus, we attempted to identify the relationship between 
the pre-operative serum IL-2Rα level and lymph node 
metastasis, and thereby assess the use of the serum IL-2Rα 
level as a predictor of lymph node metastasis, and con-
sequently as a prognostic indicator in patients with early 
gastric cancer.
METHODS
From May through December 2003, 86 patients who 
were diagnosed with early gastric cancer and underwent 
surgery at the Samsung Medical Center were enrolled as 
volunteers in the current study. Of the 86 patients, 66 were 
confirmed by pathology to have tumor invasion of the 
submucosal layer, while another 20 patients had invasion 
of the mucosal layer. These patients included 52 males and 
34 females, with an average age of 57.5 years (range, 28 to 
74 years).
Pre-operative endoscopy was used to assess the mor-
phology of the tumors and the results of pre-operative ab-
dominal computer tomography were reviewed for all 
patients. Patients were divided into two groups based on 
tumor invasion into mucosal and submucosal groups, and 
the submucosal groups was further divided into sm1, sm2, 
and sm3 according to the depth of tumor invasion, based 
on post-operative pathology. Papillary, well and moder-
ately differentiated adenocarcinoma were classified as 
‘differentiated types,’ while poorly differentiated ad-
enocarcinoma, mucinous adenocarcinoma, and signet 
ring cell carcinoma were classified as ‘undifferentiated 
types.’ The results obtained from these patients were com-
pared with 20 healthy individuals. Ethical approval was 
given by the Internal Review Board prior to commencing 
this study. 
Collection and storage of serum samples for en-
zyme-linked immunosorbent assay (ELISA)
Before each surgery, serum was collected from each pa-
tient and stored at －80
oC until assay. The levels of se-
rum-soluble IL-2Rα were measured by an ELISA using an 
interleukin-2 receptor kit (R&D Systems Inc., Minneap-
olis, MN, USA) in accordance with the manufacturer’s 
instructions. The control group for the measurement of se-
rum-soluble IL-2Rα levels consisted of 20 healthy indi-
viduals. The method used a four-fold dilution of patient 
serum (50 μL sample + 150 μL calibrator diluent RD6S) 
compared against standards and controls applied to a 
96-well plate, which was coated with monoclonal anti-
bodies against IL-2Ra.
The standards were diluted to 5,000, 2,500, 1,250, 625, 
312, and 78 pg/mL, then the secondary antibody was 
applied. The assay was performed at room temperature 
(25
oC) and incubated for 3 hours. The plates were washed 
four times, followed by incubation with a combined sub-
strate solution consisting of tetrametyl benzidine and hy-
drogen peroxide. After a 20 minutes incubation in the 
dark, substrate stopping solution was added and the ab-
sorbance was measured at 450 nm. Each assay was per-Serum maker can predict lymph node metastasis in gastric cancer 
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Characteristic Total
Serum IL-2Rα 
(SD) (U/mL)
P-value
Gender 0.143
  Female 34 (39.6) 203.57 (80.2)
  Male 52 (60.4)   235.36 (107.0)
Depth (tumor) 0.050
  Mucosa 20 (23.3) 185.17 (60.9)
  Submucosa 66 (76.7)   234.20 (104.5)
Tumor size (cm) 0.181
  ＜2  24 (27.9) 199.94 (82.0)
  ≥2 62 (72.1)   231.64 (102.9)
Differentiation 0.100
  Differentiated 48 (55.8)   237.51 (114.6)
  Undifferentiated 38 (44.2) 204.21 (69.1)
Lymph node metastasis 0.113
  No 70 (81.3) 214.77 (95.4)
  Yes 16 (18.7)   257.89 (104.8)
Endoscopy (findings) 0.318
  Elevated
a) 23 (23.9)   240.39 (124.3)
  Depressed
b) 63 (76.1) 216.37 (86.9)
Values are presented as number (%).
IL-2Rα, interleukin-2 receptor alpha; SD, standard deviation. 
a)Endoscopic protruding, flat type (I, IIa, IIb). 
b)Endoscopic 
depressed type (IIc, III).
Table 1. Relationship between serum IL-2Rα level and clinico-
pathologic variables in gastric cancer
Fig. 1. Receiver operating characteristic (ROC) curve of the 
differentiated group of early gastric cancers and the undifferen-
tiated gastric cancers. 
formed in triplicate.
Statistical analyses
All statistical analyses were performed using the SPSS 
ver. 11.0 (SPSS Inc., Chicago, IL, USA). Using the meas-
ured values, a receiver operatiing characteristic (ROC) 
curve was performed and a cut-off value was determined, 
which produced high specificity and high sensitivity. The 
risk factors of lymph node metastasis were investigated by 
univariate and multivariate analyses using a two-tailed 
chi-square test and logistic regression. The significance of 
the difference amongst means was determined by a 
Student’s t-test. A P-value ＜  0.05 was considered 
significant.
RESULTS
Among the 86 patients assessed, 16 had lymph node 
metastases (18.6%). The mean serum level of IL-2Rα in pa-
tients with gastric cancer was 222.79 ± 98.1 U/mL, which 
was significantly higher than the normal controls (131.96 ± 
95.5 U/mL; P = 0.0001). 
The correlation between the levels of serum-soluble 
IL-2Rα and the clinicopathologic findings are shown in 
Table 1. The levels of serum-soluble IL-2Rα in patients 
with submucosal invasive gastric cancer were sig-
nificantly than in the patients with mucosal invasive gas-
tric cancer (P = 0.05). We focused on whether or not the se-
rum level of IL-2Rα differed according to lymph node 
metastasis.
Although patients with lymph node metastasis had 
higher levels of serum-soluble IL-2Rα than patients with-
out lymph node metastasis, there were no significant dif-
ferences in the levels of serum-soluble IL-2Rα (257.89 ± 104 
in patients with lymph node metastasis [n = 16] and 214.77 
± 95.4 in patients without lymph node metastasis [n = 70]).
The patients were further subdivided according to dif-
ferentiation of the tumor. In the differentiated type, the se-
rum IL-2Rα level was not useful as a predictor of lymph 
node metastasis. Based on the ROC curve, the width 
(0.582) of the differentiated type was significantly less than 
the undifferentiated type (Fig. 1). Therefore, we limited 
the study to undifferentiated gastric cancer cases. 
In undifferentiated gastric cancer, the levels of se-
rum-soluble IL-2Rα in patients with lymph node meta-
stasis were significantly higher than patients without Yong-Hae Baik, et al.
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Characteristic Total 
Serum IL-2Rα 
(SD)(U/mL)
P-value
Gender 0.435
  Female 16 (42.1)   214.6 (75.7)
  Male 22 (45.9) 196.61 (64.6)
Depth 0.956
  Mucosa 10 (26.3) 203.16 (67.7)
  Submucosa 28 (73.7) 204.58 (70.8)
Tumor size (cm) 0.869
  ＜2   9 (23.7) 207.59 (45.2)
  ≥2 29 (76.3) 203.15 (90.8)
Lymph node metastasis 0.050
  No 29 (76.3) 192.29 (68.2)
  Yes   9 (23.7) 242.59 (60.1)
Endoscopy (findings) 0.632
  Elevated
a)   7 (18.4) 215.72 (44.8)
  Depressed
b) 31 (81.6) 201.60 (73.8)
Values are presented as number (%).
IL-2Rα, interleukin-2 receptor alpha; SD, standard deviation. 
a)Endoscopic protruding, flat type (I, IIa, IIb). 
b)Endoscopic 
depressed type (IIc, III).
Table 2. Relationship between serum IL-2Rα level and 
clinicopathologic variables in undifferentiated gastric cancer
Characteristic
Presence of lymph node metastasis (n=9)
OR Adjusted  No.  (%)   P-value P-value (95% CI) OR (95% CI)
Gender             0.825 0.198
 Female 4 (44.5) 1.000
 Male 5 (55.5) 1.133 
(0.251-5.121)
10.8 
(0.28-46.2)
Depth  0.750 0.353
 Mucosa 2 (22.2) 1.000    
 Submucosa 7 (77.8) 1.333 
(0.227-7.827)
             
Tumor size (cm) 0.298 0.960
 ＜4 4 (44.5)  1.000
 ≥4 5 (55.5)  2.321 
(0.467-11.545)
Serum IL-2Rα          0.022 0.028
 ＜200 2 (22.2)  1.000
 ≥200 7 (77.8)  6.650 
(1.158-38.195)
8.46 
(1.62-42.7)
Endoscopy (findings) 0.186 0.133
 Elevated
a) 1 (11.1) 1.000
 Depressed
b) 8 (88.9) 3.125 
(0.547-17.841)
OR, odds ratio; CI, confidence intervals; IL-2Rα, interleukin-2 
receptor alpha.
a)Endoscopic protruding, flat type (I, IIa, IIb). 
b)Endoscopic 
depressed type (IIc, III).
Table 3. Univariate and multivariate analyses of clinicopathologic
variables in relation to lymph node metastasis in the undif-
ferentiated group of early gastric cancer
Fig. 2. Receiver operating characteristic (ROC) curve showing the 
point of maximal sensitivity and specificity. IL-2Rα, interleukin-2 
receptor alpha. 
lymph node metastasis (P = 0.05) (Table 2). The optimal 
cut-off value of serum-soluble IL-2Rα for predicting 
lymph node metastasis in patient with early gastric cancer 
was shown to be 200 U/mL. At this cut-off point, the sensi-
tivity and specificity were 77.8% and 65.5%, respectively 
(Fig. 2).
Based on this cut-off point, we evaluated the risk factors 
for lymph node metastasis in patients with un-
differentiated gastric cancer (Table 3). As shown in multi-
variate analysis, a serum IL-2Rα level ＞200 U/mL was a 
significant risk factor for lymph node metastasis (P = 
0.028). 
DISCUSSION
The development of new treatment modalities, such as 
EMR, laparoscopic gastrectomy, and robotic surgery, has 
improved patients’ quality of life.
The application of these treatments in patients with ear-
ly gastric cancer is based on the pre-operative prediction 
of lymph node metastasis. EMR should not be performed 
if there is any evidence of lymph node metastasis, even if 
the tumor is ＜1 cm in size. In laparoscopic gastrectomy 
cases, in which lymph node metastasis is determined Serum maker can predict lymph node metastasis in gastric cancer 
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pre-operatively, the surgeon should consider more than 
D1 lymph node dissection. 
Among the methods of pre-operative evaluation, ab-
dominal CT is the most popular method of evaluation for 
lymph node metastasis; the most important criterion for 
lymph node metastasis is the size of the lymph nodes. 
Generally, a lymph node ＞10 mm in size is considered to 
represent tumor metastasis. However, the sensitivity and 
the specificity for predicting lymph node metastasis of CT 
scan is unsatisfactory, because 28% of pathologically pos-
itive lymph nodes are less than 10 mm in size [9-11]. 
Another modality for predicting lymph node metastasis in 
patients with gastric cancer is pre-operative endoscopic 
ultrasonography, which has the advantage of an accurate 
diagnostic image of not only the depths of tumor invasion, 
but also peri-gastric lymph node metastasis. 
Use of endoscopic ultrasonography implies that lymph 
node metastasis can be divided by size and marginal and 
internal echoes. When lymph node metastasis is present, 
lymph node echoes are similar to that of stomach lesions, 
presenting with irregular margins and low echo struc-
tures. The diagnosis accuracy of endoscopic ultrasono-
graphy is 55 to 75% [12].
In early gastric cancer when the tumor is confined to the 
mucosa, lymph node metastasis occurs in only 2 to 4% of 
patients. However, in cases of submucosal invasion, 
lymph node metastasis occurs in 15 to 25% of patients 
[13,14]. Lymph node metastasis is the most dangerous risk 
factor for loco-regional recurrence and distant metastasis.
Abe et al. [15] reported that the high-risk factors for 
lymph node metastasis include the following: female gen-
der; a tumor invasion of the submucosa; large tumor size; 
and tumor lymphatic channel invasion. Wu et al. [16] sug-
gested that cases with undifferentiated carcinoma, large 
tumor size, and submucosal tumor invasion have a high 
risk for lymph node metastasis. Folli et al. [17] emphasized 
that endoscopic findings and depth of tumor invasion are 
important predictors of lymph node metastasis. 
The serum IL-2Rα level is a possible alternative or ad-
juvant tool of diagnosis for pre-operative assessment of 
lymph node metastasis. Murakami et al. [18] study serum 
IL-2Rα level can predict lymph node metastasis in early 
gastric cancer regardless of cell differentiation. However 
based on the results of our study, only the serum IL-2Rα 
level in undifferentiated type were different according to 
lymph node metastasis.
Forones et al. [19] studied 23 patients using IL-2 as a tu-
mor marker associated with careinoembryonal antigen 
(CEA) and carbohydrate antigen (CA)19-9. In advanced 
gastric cancer patients, serum levels of IL-2, CEA, and 
CA19-9 are greatly increased compared to early gastric 
cancer patients. Maeta et al. [20] found that during the fol-
low-up period, a high level of IL-2 is a poor prognostic 
factor. 
Our study confirmed this result, with gastric cancer pa-
tients having an increased serum level of IL-2Rα (222.79 ± 
98.1 U/mL) compared to healthy patients (131.96 ± 95.5 
U/mL), and the level of serum IL-2Rα was shown to be a 
meaningful predictor of lymph node metastasis, not in dif-
ferentiated gastric cancer, but in undifferentiated gastric 
cancer patients, with a cut-off value of detection of gastric 
cancer lymph node metastasis based on a serum IL-2 level 
of 200 U/mL.
A limitation of current study was the small number of 
cases of lymph node metastasis in undifferentiated group, 
so statistical power was not as strong as expected. Further 
studies with a large number of patients are needed.
In conclusion, the serum level of IL-2Rα can be used as 
a predictor of lymph node metastasis in the patients with 
undifferentiated early gastric cancer, if it is used in combi-
nation with the findings of CT scan and endoscopic 
ultrasonography.
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